Skip to main content

Table 2 Confirmed Best Overall Response Based on RECIST v1.1

From: Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial

Response

With Mitotane (n = 25)

Without Mitotane (n = 25)

Overall (N = 50)

Confirmed best overall response, n (%)

 Complete response

0

0

0

 Partial response

2 (8.0)

1 (4.0)

3 (6.0)

 Stable disease

10 (40.0)

11 (44.0)

21 (42.0)

 Progressive disease

10 (40.0)

13 (52.0)

23 (46.0)

 Not evaluable

3 (6.0)

0

3 (6.0)

ORR (95% CI), %

8.0 (1.0–26.0)

4.0 (0.1–20.4)

6.0 (1.3–16.5)

Disease control rate, %

48.0

48.0

48.0